STOCK TITAN

Zomedica Corp - ZOM STOCK NEWS

Welcome to our dedicated page for Zomedica news (Ticker: ZOM), a resource for investors and traders seeking the latest updates and insights on Zomedica stock.

Overview

Zomedica Corp (NYSE American: ZOM) is an innovative veterinary healthcare company dedicated to enhancing animal health through advanced diagnostic and therapeutic solutions. Specializing in point-of-care technologies for companion animals and equines, the company offers a robust portfolio designed to address the unmet needs of clinical veterinarians and improve practice efficiencies. With a focus on novel diagnostic platforms and non-invasive therapeutic devices, Zomedica empowers veterinary professionals to lower operating costs, increase productivity, and ultimately deliver superior patient care.

Product Portfolio and Technological Innovations

Zomedica's offerings include an array of cutting-edge products that integrate advanced imaging, automated diagnostic capabilities, and innovative therapeutic modalities. The company is renowned for its TRUFORMA diagnostic platform, a system that utilizes proprietary sensor technologies for accurate and rapid testing. Alongside this, its digital cytology system and remote monitoring solutions enhance the precision of diagnoses and clinical decision-making. Additionally, Zomedica’s novel therapeutic devices are designed to accelerate healing processes and minimize patient discomfort through non-invasive methods.

Market Position and Competitive Edge

Operating within the broader veterinary health industry, Zomedica has established a strong market position by addressing both clinical and business challenges faced by veterinarians. The company differentiates itself with a deep commitment to research and development, leveraging the insights of practicing veterinary professionals to tailor its product suite. This focus on innovation has allowed Zomedica to not only meet the growing demand for efficient, point-of-care diagnostic tools but also to set new operational standards across veterinary practices. Its comprehensive solutions enable veterinarians to conduct tests quickly and accurately, thereby reducing turnaround times and enhancing patient care.

Operational Excellence and Global Reach

Headquartered in Michigan, Zomedica operates from world-class manufacturing and distribution facilities that underscore its commitment to quality and efficiency. With manufacturing operations in key U.S. regions, the company ensures consistent delivery of high-quality products to its domestic and international markets. Zomedica's strategic partnerships in various regions further complement its mission of expanding access to advanced veterinary care globally. The company’s investments in cleanroom technologies and automated production lines not only enhance manufacturing capacity but also streamline logistics and distribution processes.

Benefits to Veterinary Practices

The integrated solutions offered by Zomedica are specifically designed to improve the workflow and profitability of veterinary practices. By automating complex diagnostic procedures and providing rapid, lab-quality results at the point of care, the company enables veterinarians to focus on delivering improved patient outcomes. Enhanced diagnostic speed, reduced operational costs, and increased efficiency are key factors driving the widespread adoption of Zomedica’s technologies in veterinary clinics across varied market segments.

Commitment to Innovation and Quality Care

Underpinned by the insights of industry experts and built on robust scientific research, Zomedica remains committed to continuous improvement in veterinary care. The company’s strategic focus on innovation, combined with its rigorous quality control measures, supports a wide spectrum of diagnostic and therapeutic applications. This dedication not only bolsters the confidence of veterinary professionals in adopting its technologies but also reinforces the company’s reputation for excellence, expertise, and trustworthiness in the veterinary healthcare industry.

Conclusion

Zomedica Corp stands out as a pioneering force in the veterinary health sector by delivering comprehensive, technology-driven solutions that enhance both clinical outcomes and practice management. Through its innovative product portfolio and strategic operational excellence, Zomedica continues to influence the evolution of veterinary diagnostics and therapeutics, enabling veterinarians to provide top-tier care to companion and equine patients.

Rhea-AI Summary
Zomedica Corp. reports Q2 2023 financial results, with revenue of $6.0 million, a 43% increase compared to Q2 2022. Therapeutic segment revenue increased by 38% and diagnostic segment revenue doubled. Gross margin was 67%. Zomedica ended the quarter with $142.4 million in cash. The company expects revenue to continue increasing in subsequent periods.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.38%
Tags
-
Rhea-AI Summary
Zomedica Corp. (ZOM) CEO Larry Heaton to present at Sidoti August Virtual Investor Conference, offering point-of-care diagnostics and therapeutic products for companion animals. Investors can register for free to attend the live presentation and one-on-one meetings on August 16-17, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.59%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.43%
Tags
conferences earnings
Rhea-AI Summary
Zomedica Corp. has announced the launch of the TRUVIEW digital microscopy platform, featuring the TRUprep system and LiquiView liquid lens technology. The all-in-one TRUVIEW system combines advanced optics, automated slide preparation, and tele-pathology to improve veterinarian diagnostic confidence. The TRUprep system eliminates the need for manual slide preparation, saving technician time and improving workflow. The digital imaging and telepathology component allows veterinarians to review slides digitally or send them for external review. Zomedica will initially offer the TRUVIEW system to practices participating in its Customer Appreciation Program. The TRUVIEW microscope enhances diagnostic capabilities and streamlines workflow.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.01%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.5%
Tags
conferences
-
Rhea-AI Summary
Zomedica Corp. reports Q1 2023 financial results with revenue of $5.5 million, a 45% increase compared to Q1 2022. Gross margin was 70%. The company ended Q1 with $147.5 million in cash. Zomedica plans to introduce new product platforms in 2023 and evaluate strategic business opportunities in the animal health sector.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.98%
Tags
Rhea-AI Summary
Zomedica Corp. has exercised its option to acquire Structured Monitoring Products, Inc. (SMP), the makers of VetGuardian™ zero-touch vital signs remote monitoring system. The acquisition is based on Zomedica's previous investments in SMP. The VetGuardian system allows real-time remote monitoring of pets' vital signs without wired leads or a harness. Zomedica has been distributing the VetGuardian system since January 2023 and is expanding its launch through U.S. animal health distributors. The acquisition will involve a non-refundable deposit of $250 thousand and a definitive agreement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Summary

Zomedica Corp. (NYSE American: ZOM), a veterinary health company, announced that CEO Larry Heaton will provide a strategic update at the H.C. Wainwright Global Investment Conference on May 2, 2023, at 2:30 PM ET. This presentation will be available via webcast and can be accessed on Zomedica's website after the event.

Zomedica specializes in point-of-care diagnostics and therapeutic products for companion animals, such as dogs and cats. Their mission focuses on enhancing productivity and revenue for veterinarians while improving animal care. For more information about their products, visit www.zomedica.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.71%
Tags
conferences
Rhea-AI Summary

Zomedica Corp. (NYSE American:ZOM) is set to be featured on The RedChip Money Report airing on Bloomberg TV on April 1, 2023, at 7 p.m. ET. This interview aims to provide insights into Zomedica's operations in the veterinary health sector, focusing on products for clinical veterinarians and enhancing animal care. The show, with an estimated reach of 73 million homes in the U.S., is part of RedChip Companies' effort to highlight microcap and small-cap stocks.
For complete access to the interview, visit here.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.93%
Tags
none

FAQ

What is the current stock price of Zomedica (ZOM)?

The current stock price of Zomedica (ZOM) is $0.0973 as of March 5, 2025.

What is the market cap of Zomedica (ZOM)?

The market cap of Zomedica (ZOM) is approximately 95.3M.

What is the core business of Zomedica Corp?

Zomedica Corp focuses on providing innovative diagnostic and therapeutic solutions for veterinary applications, enhancing care for companion and equine animals.

Which markets does Zomedica serve?

The company serves the veterinary healthcare market with products used in both companion animal and equine practices across domestic and international regions.

What type of products does Zomedica offer?

Zomedica offers a range of point-of-care diagnostic platforms, imaging systems, and therapeutic devices designed to streamline practice workflows and improve patient outcomes.

How does Zomedica differentiate itself in the veterinary industry?

By integrating advanced technology with clinically-driven insights, Zomedica delivers precise, rapid diagnostic results and innovative therapeutic solutions that address critical unmet needs in veterinary practices.

What role does the TRUFORMA diagnostic platform play in their offerings?

The TRUFORMA platform provides automated, high-precision diagnostic capabilities at the point of care, reducing turnaround times and enhancing the accuracy of veterinary diagnostics.

How does Zomedica improve operational efficiencies for veterinary clinics?

Their innovative products automate complex diagnostic processes and streamline clinical workflows, leading to faster decision-making, lower costs, and improved patient care.

Why is Zomedica considered an expert in veterinary healthcare?

The company’s commitment to R&D, its science-backed product innovations, and strategic partnerships with veterinary professionals collectively reinforce its reputation for expertise and trustworthiness in the industry.
Zomedica Corp

NYSE:ZOM

ZOM Rankings

ZOM Stock Data

95.35M
961.51M
1.87%
9.37%
4.63%
Medical Devices
Pharmaceutical Preparations
Link
United States
ANN ARBOR